BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES
    1.
    发明申请
    BETA-L-2' DEOXYNUCLEOSIDES FOR THE TREATMENT OF RESISTANT HBV STRAINS AND COMBINATION THERAPIES 有权
    用于治疗耐药性HBV菌株和组合治疗的BETA-L-2'脱氧核糖核酸

    公开(公告)号:US20110172178A1

    公开(公告)日:2011-07-14

    申请号:US13052750

    申请日:2011-03-21

    摘要: It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.

    摘要翻译: 已经发现,-L-2'-脱氧核苷对具有突变的耐药性乙型肝炎病毒具有活性。 提供了一种治疗宿主中拉米夫定耐药HBV(M552V)的方法,其包括施用一种β-2'-2'-脱氧核苷或其药学上可接受的盐,酯或前药。 另外,提供了一种用于预防在初始宿主中发生拉米夫定耐药性HBV(M552V)突变的方法,其包括施用一种β-2'-脱氧核苷或其药学上可接受的盐,酯或前药。 还提供了用于预防和/或抑制宿主中HBV双突变体(L528M / M552V)的出现的方法,其包括施用&bgr。-L-2'-脱氧核苷或其药学上可接受的盐,酯或前药。

    β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
    2.
    发明授权
    β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies 有权
    &bgr; -L-2'-脱氧核苷用于治疗耐药性HBV病毒株和联合疗法

    公开(公告)号:US08158606B2

    公开(公告)日:2012-04-17

    申请号:US13052750

    申请日:2011-03-21

    摘要: It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.

    摘要翻译: 已经发现,-L-2'-脱氧核苷对具有突变的耐药性乙型肝炎病毒是有活性的。 提供了一种治疗宿主中拉米夫定耐药HBV(M552V)的方法,其包括施用一种β-2'-2'-脱氧核苷或其药学上可接受的盐,酯或前药。 另外,提供了一种用于预防在初始宿主中发生拉米夫定耐药性HBV(M552V)突变的方法,其包括施用一种β-2'-脱氧核苷或其药学上可接受的盐,酯或前药。 还提供了用于预防和/或抑制宿主中HBV双突变体(L528M / M552V)的出现的方法,其包括施用&bgr。-L-2'-脱氧核苷或其药学上可接受的盐,酯或前药。

    Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
    3.
    发明申请
    Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies 有权
    β-L-2'-脱氧核苷用于治疗耐药性HBV病毒株和组合疗法

    公开(公告)号:US20080182814A1

    公开(公告)日:2008-07-31

    申请号:US11651353

    申请日:2007-01-09

    摘要: It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.

    摘要翻译: 已经发现β-L-2'-脱氧核苷对具有突变的耐药性乙型肝炎病毒具有活性。 提供了一种治疗宿主中拉米夫定耐药性HBV(M552V)的方法,其包括施用β-L-2'-脱氧核苷或其药学上可接受的盐,酯或前药。 此外,提供了一种用于预防在初始宿主中发生拉米夫定耐药性HBV(M552V)突变的方法,其包括施用β-L-2'-脱氧核苷或其药学上可接受的盐,酯或前药。 还提供了预防和/或抑制宿主中HBV双突变体(L528M / M552V)的出现的方法,其包括施用β-L-2'-脱氧核苷或其药学上可接受的盐,酯或前药。

    Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
    4.
    发明申请
    Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies 有权
    β-L-2'-脱氧核苷用于治疗耐药性HBV病毒株和组合疗法

    公开(公告)号:US20050080034A1

    公开(公告)日:2005-04-14

    申请号:US10662641

    申请日:2003-09-15

    摘要: It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.

    摘要翻译: 已经发现β-L-2'-脱氧核苷对具有突变的耐药性乙型肝炎病毒具有活性。 提供了一种治疗宿主中拉米夫定耐药性HBV(M552V)的方法,其包括施用β-L-2'-脱氧核苷或其药学上可接受的盐,酯或前药。 此外,提供了一种用于预防在初始宿主中发生拉米夫定耐药性HBV(M552V)突变的方法,其包括施用β-L-2'-脱氧核苷或其药学上可接受的盐,酯或前药。 还提供了预防和/或抑制宿主中HBV双突变体(L528M / M552V)的出现的方法,其包括施用β-L-2'-脱氧核苷或其药学上可接受的盐,酯或前药。

    β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
    7.
    发明授权
    β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies 有权
    &bgr; -L-2'-脱氧核苷用于治疗耐药性HBV病毒株和联合疗法

    公开(公告)号:US07928086B2

    公开(公告)日:2011-04-19

    申请号:US11651353

    申请日:2007-01-09

    摘要: It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.

    摘要翻译: 已经发现,-L-2'-脱氧核苷对具有突变的耐药性乙型肝炎病毒具有活性。 提供了一种治疗宿主中拉米夫定耐药HBV(M552V)的方法,其包括施用一种β-2'-2'-脱氧核苷或其药学上可接受的盐,酯或前药。 另外,提供了一种用于预防在初始宿主中发生拉米夫定耐药性HBV(M552V)突变的方法,其包括施用一种β-2'-脱氧核苷或其药学上可接受的盐,酯或前药。 还提供了用于预防和/或抑制宿主中HBV双突变体(L528M / M552V)的出现的方法,其包括施用&bgr。-L-2'-脱氧核苷或其药学上可接受的盐,酯或前药。

    β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
    8.
    发明授权
    β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies 有权
    β-L-2'-脱氧核苷用于治疗耐药性HBV病毒株和组合疗法

    公开(公告)号:US07186700B2

    公开(公告)日:2007-03-06

    申请号:US10662641

    申请日:2003-09-15

    摘要: It has been discovered that β-L-2′-deoxynucleosides are active against drug-resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition, a method for preventing lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that includes administering a β-L-2′-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug.

    摘要翻译: 已经发现β-L-2'-脱氧核苷对具有突变的耐药性乙型肝炎病毒具有活性。 提供了一种治疗宿主中拉米夫定耐药性HBV(M552V)的方法,其包括施用β-L-2'-脱氧核苷或其药学上可接受的盐,酯或前药。 此外,提供了一种用于预防在初始宿主中发生拉米夫定耐药性HBV(M552V)突变的方法,其包括施用β-L-2'-脱氧核苷或其药学上可接受的盐,酯或前药。 还提供了预防和/或抑制宿主中HBV双突变体(L528M / M552V)的出现的方法,其包括施用β-L-2'-脱氧核苷或其药学上可接受的盐,酯或前药。